![[IPWatchdog Logo]](https://ipwatchdog.com/wp-content/themes/IPWatchdog%20-%202023/assets/images/temp/logo-small@2x.png){kind=logo}
Jeffrey D. Morton, Ph.D.
Partner
Jeffrey D. Morton, Ph.D. is a partner at Procopio, Cory, Hargreaves & Savitch LLP. He has over 15 years of experience representing both start-ups and large enterprises for their intellectual property and commercial law needs. Jeffrey has significant patent prosecution and strategic patent counseling experience in a wide range of technologies, including genomics, immunology, and gene editing technologies. Jeffrey is admitted to the bar in the United States and Canada and his practice includes providing cross-border advice to Canadian clients operating in the United States and vice versa.
Recent Articles by Jeffrey D. Morton, Ph.D.
As previously reported here, on February 28, 2022, in Interference 106,115, the Patent Trial and Appeal Board (PTAB) issued a decision in which it awarded inventive priority to the Broad Institute (Broad) over the University of California (U.C.) on an invention covering applications of the CRISPR-Cas9 gene editing system in eukaryotic cells. This decision purports to award substantial control of the CRISPR-Cas9 patent landscape to Broad. This article provides additional background on CRISPR-Cas9 technology, outlines the critical findings in Interference 106,115 that resulted in the PTAB awarding priority to Broad, and describes the impact of the PTAB’s decision for Broad, U.C., and other companies involved in the development of CRISPR-Cas9 technology.
